Actinogen Medical Expands Alzheimer’s Drug Trial to US
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2024
0mins
Source: Business Insider
Actinogen Medical Update: Actinogen Medical Limited has initiated a phase 2b/3 trial for its Alzheimer’s treatment, Xanamem, with the first US participant enrolled. The study will assess the drug's effects on cognitive and functional measures, with interim results expected in 2025 and final results in 2026.
Trial Expansion: The trial is being conducted across 25 sites in the US and Australia, highlighting Actinogen's commitment to developing innovative treatments for neurological conditions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
